Coral Laboratories Ltd to Consider Q2 FY27 Results on November 14

Coral Laboratories Ltd is scheduled to consider its standalone unaudited Q2 FY27 and half-year results on November 14, 2026, following Q1 FY27 revenue growth of 57.4% year-on-year to ₹29.6 crore and net profit growth of 107.7% to ₹5.4 crore.

When will Coral Laboratories announce Q2 FY27 results?

Coral Laboratories will hold a board meeting on Saturday, November 14, 2026, to consider and approve standalone unaudited financial results for the quarter and half year ended September 30, 2026. The company disclosed the meeting through an intimation dated November 4 under Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The agenda also allows the board to take up other business with the chairman's permission. The disclosed agenda does not mention a dividend, fund-raising proposal, acquisition, capacity addition, or any other corporate action. The results will cover the July-September quarter, which is the second quarter of FY27, and the first six months ended September 30.

The meeting follows Coral Laboratories' latest reported quarterly performance for the June 2026 quarter. Sales for that quarter stood at ₹29.62 crore, compared with ₹18.82 crore in the June 2025 quarter. Net profit was reported at ₹5.39 crore, compared with the Q1 FY27 summary figure of ₹5.4 crore after rounding.

What does the trading-window closure mean for Coral Laboratories investors?

Coral Laboratories closed its trading window from October 1, 2026, in line with its insider-trading code and the SEBI Prohibition of Insider Trading Regulations, 2015. The window will remain closed until 48 hours after the financial results are declared.

A trading-window closure restricts designated persons and others covered by the company's internal code from dealing in its securities while they may possess unpublished price-sensitive information. It is a compliance measure linked to the results process and does not itself indicate the likely direction of quarterly financial performance.

Coral Laboratories is listed on the BSE under scrip code 524506 and has ISIN INE683E01017. The provided market data places the company's share price at ₹536.25 and classifies its market capitalisation as micro cap. No price movement related to the forthcoming board meeting was provided.

How did Coral Laboratories perform in Q1 FY27?

Coral Laboratories reported a substantial year-on-year improvement in Q1 FY27, with revenue from operations rising 57.4% to ₹29.6 crore and net profit increasing 107.7% to ₹5.4 crore. The comparison base was Q1 FY26, when sales were ₹18.82 crore.

The June 2026 sales figure was also higher than the ₹26.48 crore reported in the March 2026 quarter. Quarterly sales data shows that the company recorded ₹19.03 crore in September 2025, ₹21.56 crore in December 2025, ₹26.48 crore in March 2026, and ₹29.62 crore in June 2026.

The latest quarter followed uneven performance in FY26. In Q3 FY26, Coral Laboratories reported revenue of ₹21.56 crore, down 6.19% year-on-year, while net profit declined 54.84% to ₹2.78 crore. The recovery in the June 2026 quarter therefore becomes an important reference point when the company releases its September-quarter numbers.

What recent corporate actions has Coral Laboratories completed?

Coral Laboratories approved its audited FY26 financial results and recommended a final dividend of ₹2.00 per share. At its 44th annual general meeting on September 29, 2026, the company approved audited financial statements, the final dividend, and director reappointments.

The company also approved its Cost Audit Report for FY26. In separate governance actions, the board appointed new internal and cost auditors for the following financial year. These disclosures relate to statutory and corporate-governance processes and are separate from the Q2 FY27 financial-results agenda.

Coral Laboratories had earlier announced a ₹30 crore capacity expansion at its Dehradun plant. The supplied information does not provide an implementation timeline, project status, funding structure, or financial contribution from this expansion. Investors assessing the Q2 release will therefore need to distinguish reported operating performance from announcements for which updated execution details have not been disclosed.

Why do the September-quarter results matter for Coral Laboratories?

The September-quarter results matter because they will show whether the higher sales and profit recorded in Q1 FY27 continued into the second quarter. The June-quarter revenue of ₹29.62 crore was the highest sales figure in the quarterly data provided from June 2023 through June 2026, exceeding the previous listed high of ₹32.23 crore only if comparing available figures shows it does not exceed it. The actual prior high in the table was ₹32.23 crore in September 2024.

For investors, the central disclosed indicators will be revenue, expenses, operating profit, margin, interest, depreciation, tax and net profit. The board meeting is specifically for standalone numbers, while one supplied quarterly-results table is labelled consolidated. That distinction is relevant when comparing the forthcoming release with datasets that may use a different reporting basis.

The results will also provide the first reported half-year FY27 picture. Since no guidance, order outlook, margin target, or updated capacity-expansion schedule has been disclosed in the provided material, conclusions on future earnings should await the board-approved financial statement and any accompanying company disclosure.

Conclusion

Coral Laboratories will consider standalone Q2 FY27 and first-half FY27 results on November 14, 2026, after a Q1 in which revenue reached ₹29.6 crore and net profit reached ₹5.4 crore. The result is relevant because it will test whether the sharp year-on-year improvement in the June quarter was sustained through September.

Investors should watch the reported standalone revenue, profitability and half-year figures, as well as any official update on the ₹30 crore Dehradun capacity expansion. The trading window is set to reopen 48 hours after the results declaration, while the disclosed board agenda contains no dividend or other corporate action.